Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

bupropion hydrochloride controlled-release

A controlled-release tablet formulation containing the hydrochloride salt of the aminoketone bupropion, with antidepressant activity and for potential use in promoting smoking cessation, improving sexual desire, and improving cancer-related fatigue. Bupropion is a weak blocker of the neuronal uptake of serotonin, dopamine and norepinephrine and is a central nicotinic acetylcholine receptor antagonist. Bupropion may also reduce circulating levels of tumor necrosis factor (TNF) and normalize hypothalamic-pituitary-adrenal (HPA) axis functioning, which is dysregulated in certain cases of cancer-related fatigue. The controlled-release formulation results in a higher concentration of the drug in the body over an extended period, thereby permitting a reduction in the frequency of dosing.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:bupropion HCl controlled-release
bupropion HCl extended release
bupropion hydrochloride extended-release
US brand name:Aplenzin
Wellbutrin SR
Wellbutrin XL
Zyban
Foreign brand name:Forfivo XL
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search